Even though behaving as a CD44 agonist, A6 treatment reduced the migration of cancer cells in vitro and demonstrated increased progression-free survival in patients with ovarian cancer with a positive safety profile (Gold et al. 2012). This evidence concerns the gene CD44 and ovarian carcinoma.